Supplementary Table 2 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston; Jean Yves Blay; Jonathan C. Trent; Claudia Valverde; Mark Agulnik; Mrinal M. Gounder; Axel Le Cesne; Meredith McKean; Michael J. Wagner; Silvia Stacchiotti; Samuel Agresta; Alfonso Quintás‐Cardama; Sarah A. Reilly; Kathleen Healy; Denice Hickman; Tina Zhao; Alex Ballesteros‐Perez; Alexis Khalil; Michael P. Collins; Jessica Piel; Kim Horrigan; Ariel Lefkovith; Scott Innis; Alexander J. Lazar; Gregory M. Coté; Andrew J. Wagner

doi:10.1158/1078-0432.28431308

Supplementary Table 2 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean Yves Blay, Jonathan C. Trent, Claudia Valverde, Mark Agulnik, Mrinal M. Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás‐Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros‐Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan, Ariel Lefkovith, Scott Innis, Alexander J. Lazar, Gregory M. Coté, Andrew J. Wagner

Dataset

Supplementary Table 4 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean Yves Blay, Jonathan C. Trent, Claudia Valverde, Mark Agulnik, Mrinal M. Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás‐Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros‐Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan,

Dataset

Supplementary Table 5 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean Yves Blay, Jonathan C. Trent, Claudia Valverde, Mark Agulnik, Mrinal M. Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás‐Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros‐Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan,

Dataset

Supplementary Table 5 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean Yves Blay, Jonathan C. Trent, Claudia Valverde, Mark Agulnik, Mrinal M. Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás‐Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros‐Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan,

Dataset

Supplementary Table 7 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean Yves Blay, Jonathan C. Trent, Claudia Valverde, Mark Agulnik, Mrinal M. Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás‐Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros‐Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan,

Supplementary Table 2 from A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

Abstract

Discussion(0)

Related publications